MedTrace Logo

Ropivacaine Concentration and Rebound Pain

NCT06950372 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-20

No results posted yet for this study

Summary

The goal of this clinical trial is to see if the concentration of a local anesthetic (ropivacaine) in peripheral nerve block is related to the severness of pain after surgery of distal radius fractures in adults.

The main questions it aims to answer are:

* Is concentration of ropivacaine related to severeness, duration and type of postoperative pain?
* Is concentration of ropivacaine related to analgetic consumption after surgery?
* Is concentration of ropivacaine related to block sucess rate during surgery and patient satisfaction after surgery?

Researchers will compare ropivacaine 3.75 mg/ml and 7.5 mg/ml used in brachial plexus peripheral nerve block. Participipants are randomized to one of the two concentrations. The peripheral nerve block is standard anesthetic treatment for distal radius fractures scheduled for volar plate surgery at Oslo University Hospital. All other treatment for the condition will be the same as standard treatment.

Participants will answer a questionnaire regarding pain, physical function, medication and life quality at different points of time after surgery, up to 6 weeks after surgery.

Conditions

  • Radius Fracture Distal
  • Rebound Pain

Interventions

DRUG

Ropivacaine concentration low

Brachial plexus nerve block with ropivacaine 3.75 mg/ml

DRUG

Ropivacaine concentration high

Brachial plexus nerve block with ropivacaine 7.5 mg/ml

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Anette Aasen, MD, Anesthesiologist · University of Oslo and Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-14
Primary Completion
2026-04-08
Completion
2026-04-08

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06950372 on ClinicalTrials.gov